

Ascelia Pharma - All eyes on the partner strategy and the FDA process

After the recent rights issue, Ascelia has SEK 75.3 in cash before support from warrants, and the company has a runway to end 2025. The Full Study Report for Orvigance is completed, and the next stage is to engage in pre-submission meetings with the FDA on the way to a formal submission by mid-2025. Orvigance continues to feature at conferences, which is important as Ascelia is pursuing a partner strategy for the future launch of Orvigance.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Ascelia Pharma - All eyes on the partner strategy and the FDA process](#)